A Phase 2 Study of the Latanoprost Punctal Plug Delivery System in Subjects With Ocular Hypertension or Open-Angle Glaucoma

Phase 2

Withdrawn

• Conditions: Glaucoma; Ocular Hypertension
• Interventions: Drug: Latanoprost-PPDS

• Registration Number: NCT00855517
• Lead Sponsor: Mati Therapeutics Inc.

Brief Summary

The purpose of this study is to evaluate IOP response to experimental dose of Latanoprost- PPDS in subjects with ocular hypertension or open-angle glaucoma.

Detailed Description

Not available

Study Timeline

• Study Start: 2009-03
• Study First Submitted: 2009-03-02
• Study First Submitted QC: 2009-03-03
• Study First Posted: 2009-03-04
• Primary Completion: 2009-07
• Study Completion: 2009-07
• Status Verified: 2013-09
• Last Update Submitted: 2013-09-16
• Last Update Posted: 2013-09-17

Recruitment & Eligibility

• Status: WITHDRAWN
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• Over 18 yrs of age with ocular hypertension or open-angle glaucoma
• Subjects who have a best corrected visual acuity of 20/100 or better

Exclusion Criteria

• Subjects who wear contact lenses.
• Uncontrolled medical conditions
• Subjects requiring chronic topical artifical tears, lubricants and/or requiring any other chronic topical medications
• Subjects who have a history of chronic or recurrent inflammatory eye disease

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Punctal Plug	Latanoprost-PPDS	-

Primary Outcome Measures

Name	Time	Method
IOP change from baseline	6 weeks